(Q51798935)

English

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.

scientific article published in January 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

phase I clinical trial

0 references

United States of America

0 references

author name string

Mark G Carmichael

1

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

Linda C Benavides

2

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

Jarrod P Holmes

3

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

Jeremy D Gates

4

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

Elizabeth A Mittendorf

5

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

Sathibalan Ponniah

6

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

George E Peoples

7

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

language of work or name

0 references

publication date

1 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

116

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

2

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

292-301

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Peptides naturally presented by MHC class I molecules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Editorial: Measurement of delayed skin-test responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24756

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24756

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 April 2018

http://europepmc.org/abstract/MED/19924797

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51798935&oldid=2185167528"